[go: up one dir, main page]

DK1503788T3 - Behandling af alpha-galactosidase A-deficiens - Google Patents

Behandling af alpha-galactosidase A-deficiens

Info

Publication number
DK1503788T3
DK1503788T3 DK03726489.2T DK03726489T DK1503788T3 DK 1503788 T3 DK1503788 T3 DK 1503788T3 DK 03726489 T DK03726489 T DK 03726489T DK 1503788 T3 DK1503788 T3 DK 1503788T3
Authority
DK
Denmark
Prior art keywords
deficiency
galactosidase
alpha
treatment
methods
Prior art date
Application number
DK03726489.2T
Other languages
English (en)
Inventor
Douglas A Treco
Kenneth Loveday
Marianne Borowski
Original Assignee
Shire Human Genetic Therapies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies
Application granted granted Critical
Publication of DK1503788T3 publication Critical patent/DK1503788T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/54—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving glucose or galactose
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
DK03726489.2T 2002-04-25 2003-04-25 Behandling af alpha-galactosidase A-deficiens DK1503788T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37558402P 2002-04-25 2002-04-25
PCT/US2003/013063 WO2003090695A2 (en) 2002-04-25 2003-04-25 TREATMENT OF α-GALACTOSIDASE A DEFICIENCY

Publications (1)

Publication Number Publication Date
DK1503788T3 true DK1503788T3 (da) 2011-10-17

Family

ID=29270665

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03726489.2T DK1503788T3 (da) 2002-04-25 2003-04-25 Behandling af alpha-galactosidase A-deficiens

Country Status (12)

Country Link
US (6) US20040071686A1 (da)
EP (2) EP1503788B1 (da)
JP (5) JP5570677B2 (da)
AT (1) ATE514430T1 (da)
AU (2) AU2003228722B2 (da)
BR (2) BR122017016940B8 (da)
CA (1) CA2483270C (da)
DK (1) DK1503788T3 (da)
ES (1) ES2367257T3 (da)
IL (4) IL164757A0 (da)
NZ (1) NZ536361A (da)
WO (1) WO2003090695A2 (da)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5570677B2 (ja) 2002-04-25 2014-08-13 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド α−ガラクトシダーゼＡ欠損症の治療
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
AU2005282449B2 (en) 2004-09-07 2011-07-14 Velico Medical, Inc. Apparatus for prolonging survival of platelets
ATE495667T1 (de) * 2004-10-15 2011-02-15 Velico Medical Inc Zusammensetzungen und verfahren für die verlängerung der überlebensdauer von blutplättchen
WO2007097934A2 (en) * 2006-02-17 2007-08-30 Elusys Therapeutics, Inc. Methods and compositions for using erythrocytes as carriers for delivery of drugs
WO2008075957A1 (en) * 2006-12-21 2008-06-26 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Treatment of fabry disease
EP2137296A2 (en) * 2007-03-23 2009-12-30 Wisconsin Alumni Research Foundation Somatic cell reprogramming
BRPI0815324A2 (pt) 2007-08-20 2015-07-14 Protalix Ltd "conjugado protêico que contém sacarídeos, processo de separação do conjugado protêico que contém sacarídeos, composição farmacêutica do conjugado protêico que contém sacarídeos, uso do conjugado protêico que contém sacarídeos e composto do conjugado protêico que contém sacarídeos"
EP2185187A1 (en) * 2007-08-29 2010-05-19 Shire Human Genetic Therapies, Inc. Subcutaneous administration of alpha-galatosidase a
US20120230974A1 (en) * 2009-11-17 2012-09-13 Protalix Ltd Alkaline alpha galactosidase for the treatment of fabry disease
US9194011B2 (en) 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
PT3626258T (pt) 2010-06-25 2021-10-19 Shire Human Genetic Therapies Métodos e composições para fornecimento ao snc de iduronato-2-sulfatase
MX2013000320A (es) 2010-06-25 2013-06-05 Shire Human Genetic Therapies Composiciones y metodos para suministro al sistema nervioso central de heparan n-sulfatasa.
DK2588130T3 (da) * 2010-06-25 2016-10-24 Shire Human Genetic Therapies Cns-afgivelse af terapeutiske midler
NZ605873A (en) 2010-06-25 2015-02-27 Shire Human Genetic Therapies Methods and compositions for cns delivery of arylsulfatase a
HRP20191924T1 (hr) 2010-06-25 2020-01-10 Shire Human Genetic Therapies, Inc. Postupci i sastavi za isporuku iduronat-2-sulfataze u cns
EP4201475A1 (en) 2011-01-03 2023-06-28 The Regents of the University of California High density epidural stimulation for facilitation of locomotion, posture, voluntary movement, and recovery of autonomic, sexual, vasomotor, and cognitive function after neurological injury
ES2774190T3 (es) 2011-01-20 2020-07-17 Protalix Ltd Composiciones de alfa-galactosidasa
US9260743B2 (en) * 2011-07-14 2016-02-16 Grifols. S.A. Rapid and accurate analysis of protein sialylation
US9393409B2 (en) 2011-11-11 2016-07-19 Neuroenabling Technologies, Inc. Non invasive neuromodulation device for enabling recovery of motor, sensory, autonomic, sexual, vasomotor and cognitive function
WO2013096899A2 (en) 2011-12-23 2013-06-27 Shire Human Genetic Therapies, Inc. Stable formulations for cns delivery of arylsulfatase a
US10155027B2 (en) 2012-07-17 2018-12-18 Amicus Therapeutics, Inc. Alpha-galactosidase A and 1-deoxygalactonojirimycin co-formulation for the treatment of fabry disease
WO2014014938A1 (en) * 2012-07-17 2014-01-23 Amicus Therapeutics, Inc. Alpha-galactosidase a and 1-deoxygalactonojirimycin co-formulation
AU2014228794B2 (en) 2013-03-15 2019-04-18 The Regents Of The University Of California Multi-site transcutaneous electrical stimulation of the spinal cord for facilitation of locomotion
EP3049148B1 (en) 2013-09-27 2020-05-20 The Regents Of The University Of California Engaging the cervical spinal cord circuitry to re-enable volitional control of hand function in tetraplegic subjects
HUE071397T2 (hu) * 2013-10-31 2025-08-28 Amgen Inc Monenzin alkalmazása rekombináns fehérjék glikozilációjának szabályozására
KR102438885B1 (ko) * 2014-12-22 2022-09-01 코덱시스, 인코포레이티드 인간 알파-갈락토시다제 변이체
US9981021B1 (en) 2015-04-09 2018-05-29 Kinetiq, Inc. Subcutaneous therapeutic enzyme formulations, uses, and methods for generating thereof
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
WO2017170896A1 (ja) * 2016-03-30 2017-10-05 国立大学法人徳島大学 マンノース－６－リン酸基含有糖蛋白質の製造方法、及び蛍光基結合型マンノース－６－リン酸基含有糖蛋白質の細胞内分布を検出する方法
US12194079B2 (en) * 2017-01-05 2025-01-14 Protalix Ltd. Therapeutic regimen for the treatment of Fabry using stabilized alpha-galactosidase
WO2018132471A1 (en) * 2017-01-10 2018-07-19 Amicus Therapeutics, Inc. Recombinant alpha-galactosidase a for treatment of fabry disease
EP4473909A3 (en) 2017-02-17 2025-01-29 The University of British Columbia Apparatus and methods for maintaining physiological functions
WO2018217791A1 (en) 2017-05-23 2018-11-29 The Regents Of The University Of California Accessing spinal networks to address sexual dysfunction
EP3974021B1 (en) 2017-06-30 2023-06-14 ONWARD Medical N.V. A system for neuromodulation
US20200206323A1 (en) * 2017-09-08 2020-07-02 The Nemours Foundation An agent, a device and a blood-circulation system for treating lysosomal storage diseases, and a method for treating lysosomal storage diseases
US12357828B2 (en) 2017-12-05 2025-07-15 Ecole Polytechnique Federale De Lausanne (Epfl) System for planning and/or providing neuromodulation
US11992684B2 (en) 2017-12-05 2024-05-28 Ecole Polytechnique Federale De Lausanne (Epfl) System for planning and/or providing neuromodulation
JP2021534877A (ja) 2018-08-23 2021-12-16 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California 神経根麻痺、馬尾症候群、及び上肢機能の回復のための非侵襲性脊髄刺激
EP3653256B1 (en) 2018-11-13 2022-03-30 ONWARD Medical N.V. Control system for movement reconstruction and/or restoration for a patient
CN113544268A (zh) 2018-12-20 2021-10-22 科德克希思公司 人类α半乳糖苷酶变体
EP3695878B1 (en) 2019-02-12 2023-04-19 ONWARD Medical N.V. A system for neuromodulation
DE19211698T1 (de) 2019-11-27 2021-09-02 Onward Medical B.V. Neuromodulation system
EP3827875B1 (en) 2019-11-27 2023-07-05 ONWARD Medical N.V. Neuromodulation system
AR121457A1 (es) * 2020-02-28 2022-06-08 Codexis Inc VARIANTES DE a-GALACTOSIDASA HUMANA

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US658567A (en) * 1899-10-14 1900-09-25 Elmer G Howard Threshing-machine attachment.
US4407957A (en) * 1981-03-13 1983-10-04 Damon Corporation Reversible microencapsulation of a core material
DE3580384D1 (de) * 1984-04-09 1990-12-13 Toyo Boseki Praeparat mit verzoegerter freigabe zum aufbringen auf die schleimhaeute der mundhoehle.
US4764376A (en) * 1984-06-18 1988-08-16 Eli Lilly And Company Method of inhibiting aromatase
GB8530631D0 (en) * 1985-12-12 1986-01-22 Ciba Geigy Ag Thrombin inhibitors
US4764378A (en) 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
US5272066A (en) * 1986-03-07 1993-12-21 Massachusetts Institute Of Technology Synthetic method for enhancing glycoprotein stability
US6048729A (en) 1987-05-01 2000-04-11 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
FR2619719B1 (fr) 1987-09-01 1991-05-10 Sanofi Sa Procede d'obtention d'interleukine-2 a partir de cellules eucaryotes, vecteurs necessaires a sa mise en oeuvre et lignees cellulaires hautement productrices
EP0463109A4 (en) 1989-03-24 1992-11-19 Research Corporation Technologies, Inc. Recombinant alpha-galactosidase, a therapy for fabry disease
US5179023A (en) * 1989-03-24 1993-01-12 Research Corporation Technologies, Inc. Recombinant α-galactosidase a therapy for Fabry disease
NZ234453A (en) 1989-07-13 1993-01-27 Sanofi Sa Recombinant dna encoding urate oxidase, and vector, host, protein and pharmaceutical compositions associated therewith
KR0159107B1 (ko) * 1989-07-13 1998-11-16 쟝 르쌍드뢰 우레이트 산화효소 활성 단백질, 이 단백질을 암호화하는 재조합 유전자, 발현 벡터, 미생물 및 형질전환세포
WO1991003556A1 (en) * 1989-09-05 1991-03-21 Biotechnology Australia Pty Ltd Recombinant product
JP2688854B2 (ja) 1989-10-27 1997-12-10 株式会社ホーネンコーポレーション 糖転移活性の強いα―ガラクトシダーゼの製造法
US5661132A (en) * 1989-12-14 1997-08-26 Auragen, Inc. Wound healing
US5697901A (en) * 1989-12-14 1997-12-16 Elof Eriksson Gene delivery by microneedle injection
AU8768191A (en) 1990-09-28 1992-04-28 Upjohn Company, The Transgenic animals with alzheimer's amyloid precursor gene
US5401650A (en) * 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
US5356804A (en) 1990-10-24 1994-10-18 Mount Sinai School Of Medicine Of The City Of New York Cloning and expression of biologically active human α-galactosidase A
CA2099876C (en) 1991-01-21 2002-03-26 Michael L. Hayes Production of enzymatically active glucocerebrosidase from recombinant cells
DK0585368T3 (da) 1991-04-25 1998-03-16 Univ Brown Res Found Implanterbart biokompatibelt immunisolatorisk vehikel til afgivelse af udvalgte terapeutiske produkter
CA2112674C (en) 1991-07-02 2005-10-04 John S. Patton Method and device for delivering aerosolized medicaments
US5750376A (en) * 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
CA2098599A1 (en) 1991-10-16 1993-04-17 William F. Swain Particle-mediated transformation of animal somatic cells
US5968502A (en) 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US6063630A (en) 1991-11-05 2000-05-16 Transkaryotic Therapies, Inc. Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
US6270989B1 (en) 1991-11-05 2001-08-07 Transkaryotic Therapies, Inc. Protein production and delivery
NZ245015A (en) 1991-11-05 1995-12-21 Transkaryotic Therapies Inc Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
US5858751A (en) * 1992-03-09 1999-01-12 The Regents Of The University Of California Compositions and methods for producing sialyltransferases
DE69312487T2 (de) * 1992-05-18 1997-11-27 Minnesota Mining & Mfg Einrichtung zur transmucosalen wirkstoffabgabe
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5804413A (en) * 1992-07-31 1998-09-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
KR100291620B1 (ko) 1992-09-29 2001-10-24 추후제출 부갑상선호르몬의활성단편의폐를통한전달방법
US6329191B1 (en) 1993-08-30 2001-12-11 Hawaii Biotechnology Group, Inc. DNA encoding recombinant coffee bean alpha-galactosidase
JPH09508783A (ja) * 1993-09-23 1997-09-09 ニユー・イングランド・バイオレイブス・インコーポレイテツド 新規なグリコシダーゼの単離及び組成物
DE4339605A1 (de) 1993-11-20 1995-05-24 Beiersdorf Ag Desodorierende Wirkstoffkombinationen auf der Basis von alpha, omega-Alkandicarbonsäuren und Fettsäurepartialglyceriden
US5843015A (en) 1993-12-28 1998-12-01 Becton Dickinson And Company Molecules for iontophoretic delivery
US5789247A (en) * 1994-04-01 1998-08-04 Ballay; Annick Expression in non-tumoral human lymphoblastoid lines with an integrative vector
FR2718357B1 (fr) 1994-04-06 1997-10-03 Defarges Alain Moreau Perfectionnements apportés à un dispositif d'injection par jet sans aiguille.
US5834251A (en) * 1994-12-30 1998-11-10 Alko Group Ltd. Methods of modifying carbohydrate moieties
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5780014A (en) * 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
US6566089B1 (en) * 1996-09-04 2003-05-20 Tularik Inc. Cell-based drug screens for regulators of gene expression
US6458574B1 (en) 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US6083725A (en) 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
DE69732129T2 (de) 1996-09-13 2005-12-08 Transkaryotic Therapies, Inc., Cambridge THERAPIE FÜR alpha GALACTOSIDASE A INSUFFIZIENZ
IL139432A0 (en) 1998-05-07 2001-11-25 Transkaryotic Therapies Inc Modifying the expression of the fsh beta gene by homologous recombination
JP2002513579A (ja) 1998-05-07 2002-05-14 トランスカリョティック セラピーズ インコーポレーテッド タンパク質を産生および送達するためのｇ−ｃｓｆ遺伝子コード領域の上流のゲノム配列
IL125423A (en) * 1998-07-20 2004-08-31 Israel State Alkaline alpha-galactosidase having broad substrate specificity
US6749851B2 (en) * 2001-08-31 2004-06-15 Clearant, Inc. Methods for sterilizing preparations of digestive enzymes
JP5570677B2 (ja) * 2002-04-25 2014-08-13 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド α−ガラクトシダーゼＡ欠損症の治療

Also Published As

Publication number Publication date
BR0309665A (pt) 2005-08-16
NZ536361A (en) 2008-05-30
US9523113B2 (en) 2016-12-20
EP1503788A4 (en) 2008-09-03
WO2003090695A2 (en) 2003-11-06
US7833742B2 (en) 2010-11-16
US11116823B2 (en) 2021-09-14
JP5570677B2 (ja) 2014-08-13
US20110002908A1 (en) 2011-01-06
BR122017016940B8 (pt) 2021-07-27
JP5981151B2 (ja) 2016-08-31
JP2016180003A (ja) 2016-10-13
AU2003228722A1 (en) 2003-11-10
BRPI0309665B1 (pt) 2019-07-16
US20040071686A1 (en) 2004-04-15
ES2367257T3 (es) 2011-10-31
ATE514430T1 (de) 2011-07-15
IL220043B (en) 2018-02-28
IL257056B (en) 2021-03-25
IL257056A (en) 2018-06-28
US9267166B2 (en) 2016-02-23
US20060177433A1 (en) 2006-08-10
EP1503788B1 (en) 2011-06-29
EP1503788A2 (en) 2005-02-09
JP6225224B2 (ja) 2017-11-01
IL220043A0 (en) 2012-06-28
AU2003228722B2 (en) 2009-06-25
BRPI0309665B8 (pt) 2021-05-25
WO2003090695A3 (en) 2004-05-06
US20160184409A1 (en) 2016-06-30
JP2012140431A (ja) 2012-07-26
CA2483270A1 (en) 2003-11-06
IL280818B (en) 2021-12-01
EP2361631A1 (en) 2011-08-31
JP2005538941A (ja) 2005-12-22
HK1073608A1 (en) 2005-10-14
AU2009217430A1 (en) 2009-10-15
CA2483270C (en) 2015-03-31
IL164757A0 (en) 2005-12-18
JP2018016630A (ja) 2018-02-01
US10245304B2 (en) 2019-04-02
JP6492139B2 (ja) 2019-03-27
US20170216411A1 (en) 2017-08-03
JP2014196343A (ja) 2014-10-16
AU2009217430B2 (en) 2012-10-18
IL280818A (en) 2021-04-29
BR122017016940B1 (pt) 2020-11-10
US20190255156A1 (en) 2019-08-22

Similar Documents

Publication Publication Date Title
DK1503788T3 (da) Behandling af alpha-galactosidase A-deficiens
NO20034056D0 (no) Proliferative sykdommer
PL374865A1 (en) Treatment of tnf alpha related disorders
DE60314500D1 (de) Diaminopyrimidine und deren verwendung als angiogenesehemmer
DE60328797D1 (de) Blutbehandlungsgerät
CY1107439T1 (el) Μεθοδοι προληψης και θεραπειας μολυνσης απο ιο του γενους flavivirus σε ζωα
DE60322582D1 (de) Oberflächenbehandlung von medizinischem gerät
DE60137337D1 (de) Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
DE60220220D1 (de) Blutbehandlungssystem
DK1553950T3 (da) Terapeutisk behandling
ITMI20030897A1 (it) Procedimento e apparecchiatura per frazionare sangue.
DK1603584T3 (da) Aplidine til behandling af multipelt myelom
NO20053903D0 (no) Nukleotidlipidesterderivater.
BR0302037B1 (pt) método e aparelho de tratamento de costura.
FI20040531A7 (fi) Insuliiniresistenttien tilojen hoitaminen ja diagnosointi
EA200500774A1 (ru) Новая синергетическая комбинация, включающая рофлумиласт и формотерол
NO20045343L (no) Ny kombinasjon for behandling av luftveisforstyrrelser
ITRM20020308A1 (it) Apparecchiatura per trattamenti terapeutici, e relativo metodo.
NO20022747L (no) Behandlingsstol
ZA200103745B (en) Therapeutic light source and method.
ITBO20020613A1 (it) Apparecchiatura per il trattamento e la pulizia dentale.
NO20011900L (no) Brönnbehandlingsfluider og fremgangsmåter for anvendelse derav
ZA200103743B (en) Therapeutic light source and method.
ITMI20022446A1 (it) Sostanze e metodi di trattamento anti-androgenetico
BR8303683Y1 (pt) disposiÇço em aparelho para tratamento, particularmente da regiço da face e pescoÇo